DE60134430D1 - Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe - Google Patents
Verfahren zur behandlung von erkrankungen im zusammenhang mit apoeInfo
- Publication number
- DE60134430D1 DE60134430D1 DE60134430T DE60134430T DE60134430D1 DE 60134430 D1 DE60134430 D1 DE 60134430D1 DE 60134430 T DE60134430 T DE 60134430T DE 60134430 T DE60134430 T DE 60134430T DE 60134430 D1 DE60134430 D1 DE 60134430D1
- Authority
- DE
- Germany
- Prior art keywords
- apoe
- methods
- carboxyl
- invention further
- further provides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101150037123 APOE gene Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 102100029470 Apolipoprotein E Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 101710095339 Apolipoprotein E Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24573700P | 2000-11-03 | 2000-11-03 | |
| PCT/US2001/051172 WO2002038108A2 (en) | 2000-11-03 | 2001-11-02 | Methods of treating disorders related to apoe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60134430D1 true DE60134430D1 (de) | 2008-07-24 |
Family
ID=22927880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60134430T Expired - Lifetime DE60134430D1 (de) | 2000-11-03 | 2001-11-02 | Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6787519B2 (de) |
| EP (1) | EP1443816B1 (de) |
| JP (1) | JP4399160B2 (de) |
| AT (1) | ATE398177T1 (de) |
| AU (1) | AU2002239766B9 (de) |
| CA (1) | CA2426030C (de) |
| DE (1) | DE60134430D1 (de) |
| WO (1) | WO2002038108A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053172A2 (en) * | 2000-12-29 | 2002-07-11 | Kimberly-Clark Worldwide, Inc. | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
| US7682795B2 (en) | 2002-07-30 | 2010-03-23 | The J. David Gladstone Institutes | Method of diagnosing Alzheimer's Disease |
| US7612179B2 (en) * | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| KR20060120161A (ko) * | 2003-11-28 | 2006-11-24 | 아스트라제네카 아베 | 항체 |
| US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
| WO2007075318A2 (en) * | 2005-12-07 | 2007-07-05 | The J. David Gladstone Institutes | Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof |
| UA94734C2 (ru) | 2006-03-30 | 2011-06-10 | Глаксо Груп Лимитед | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ |
| US20090136456A1 (en) * | 2006-12-22 | 2009-05-28 | Yadong Huang | Methods of treating neurodegenerative disorders |
| EP2376090A4 (de) * | 2008-11-21 | 2012-11-28 | David Gladstone Inst | Unterdrückung der apoe-spaltaktivität bei der behandlung von erkrankungen im zusammenhang mit apoe |
| US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
| US9102717B2 (en) | 2010-03-01 | 2015-08-11 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| EP3757121A1 (de) * | 2019-06-28 | 2020-12-30 | Eisai R&D Management Co., Ltd. | Fragmente von apolipoprotein e |
| CN116554303A (zh) * | 2022-01-30 | 2023-08-08 | 斯莱普泰(上海)生物医药科技有限公司 | 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
| US5288707A (en) * | 1990-08-13 | 1994-02-22 | Sandoz Ltd. | Borolysine peptidomimetics |
| US5650508A (en) * | 1991-12-27 | 1997-07-22 | Georgia Tech Research Corporation | Peptide ketoamides |
| GB9502985D0 (en) * | 1995-02-16 | 1995-04-05 | Thrombosis Res Inst | Enzyme inhibitors |
| EP0883405B1 (de) * | 1995-12-29 | 2004-02-25 | 3-Dimensional Pharmaceuticals, Inc. | Amidino proteaseinhibitoren |
| EP1039883A4 (de) * | 1996-07-09 | 2001-09-26 | Keith A Crutcher | Verfahren zur behandlung apolipoprotein e bedingter krankheiten |
| JPH1149739A (ja) * | 1997-08-05 | 1999-02-23 | Nippon Steel Corp | 新規な酸無水物及びキモトリプシン様プロテアーゼ阻害剤 |
| US6046381A (en) * | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
-
2001
- 2001-11-02 EP EP01987564A patent/EP1443816B1/de not_active Expired - Lifetime
- 2001-11-02 DE DE60134430T patent/DE60134430D1/de not_active Expired - Lifetime
- 2001-11-02 JP JP2002540698A patent/JP4399160B2/ja not_active Expired - Fee Related
- 2001-11-02 CA CA2426030A patent/CA2426030C/en not_active Expired - Fee Related
- 2001-11-02 US US10/033,526 patent/US6787519B2/en not_active Expired - Fee Related
- 2001-11-02 WO PCT/US2001/051172 patent/WO2002038108A2/en active Application Filing
- 2001-11-02 AU AU2002239766A patent/AU2002239766B9/en not_active Ceased
- 2001-11-02 AT AT01987564T patent/ATE398177T1/de not_active IP Right Cessation
-
2004
- 2004-04-07 US US10/820,618 patent/US7700304B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002038108A2 (en) | 2002-05-16 |
| EP1443816B1 (de) | 2008-06-11 |
| ATE398177T1 (de) | 2008-07-15 |
| CA2426030A1 (en) | 2002-05-16 |
| US20020147999A1 (en) | 2002-10-10 |
| EP1443816A2 (de) | 2004-08-11 |
| US20040268423A1 (en) | 2004-12-30 |
| JP2004516825A (ja) | 2004-06-10 |
| US7700304B2 (en) | 2010-04-20 |
| JP4399160B2 (ja) | 2010-01-13 |
| US6787519B2 (en) | 2004-09-07 |
| AU3976602A (en) | 2002-05-21 |
| CA2426030C (en) | 2013-12-31 |
| AU2002239766B2 (en) | 2006-11-09 |
| AU2002239766B9 (en) | 2007-04-05 |
| WO2002038108A3 (en) | 2004-05-06 |
| EP1443816A4 (de) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60134430D1 (de) | Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe | |
| Casas et al. | Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model | |
| Fournier et al. | Emergence and evolution of the renin–angiotensin–aldosterone system | |
| Postina et al. | A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model | |
| Philipson et al. | Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease | |
| Christensen et al. | Inactivation of the hereditary spastic paraplegia-associated Hspd1 gene encoding the Hsp60 chaperone results in early embryonic lethality in mice | |
| AU2005224992B2 (en) | Transgenic model for Alzheimer's disease | |
| ATE170082T1 (de) | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen | |
| ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| AR031717A1 (es) | Metodo para producir una proteina que es dominio de una proteina que es una proteina funcional; proceso para expresar selectivamente exones que codifican dicha proteina; gen recombinante integrado en el gen de celulas eucariotas, que comprende dicho exon; constructos de dna para producir dichas prot | |
| ZA200703426B (en) | Plants having improved growth characteristics and method for making the same | |
| JP2009525046A5 (de) | ||
| NO20060101L (no) | Forsterkning av oligodendrocyttdifferensiering | |
| Kobori et al. | Large scale isolation of osteoclast‐specific genes by an improved method involving the preparation of a subtracted cDNA library | |
| Hutter et al. | Differential roles of miR‐15a/16‐1 and miR‐497/195 clusters in immune cell development and homeostasis | |
| IL174726A (en) | Non-human animals with transgenic nucleic acid encoded by a mutant perinylin 1 protein | |
| ATE389017T1 (de) | Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) | |
| ATE431420T1 (de) | Gen-targeting-tiermodell für die wechselwirkung der apolipoprotein e4-domäne und verwendungen davon | |
| ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| Okado et al. | Developmental regulation of Xenopus β-amyloid precursor protein gene expression | |
| KR100463992B1 (ko) | 2차원 젤 전기영동에 의한 염색체 말단의 고리 형성 확인방법 | |
| WO2003089609A3 (en) | Short fragment homologous replacement to provide bse resistant cattle | |
| EP1255437B1 (de) | Transgenes tier welches ein mehrfach-mutiertes presenilin-1 exprimiert | |
| Matsui et al. | Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein | |
| ATE487942T1 (de) | Verfahren zur erkennung neurologischer erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |